PALB2 and cancer: Loss of the integral HR pathway components in cancers with non-BRCA HR defects due to germline or somatic mutations in PALB2, RAD51B, RAD51C, or RAD51D, or their inactivation through promoter methylation, might be the cause of olaparib susceptibility [42].